GABA and schizophrenia: a review of basic science and clinical studies - PubMed (original) (raw)

Review

GABA and schizophrenia: a review of basic science and clinical studies

Adel Wassef et al. J Clin Psychopharmacol. 2003 Dec.

Abstract

Background: A converging body of evidence implicates the gamma-aminobutyric acid (GABA) neurotransmitter system in the pathogenesis of schizophrenia.

Methods: The authors review neuroscience literature and clinical studies investigating the role of the GABA system in the pathophysiology of schizophrenia. First, a background on the GABA system is provided, including GABA pharmacology and neuroanatomy of GABAergic neurons. Results from basic science schizophrenia animal models and human studies are reviewed. The role of GABA in cognitive dysfunction in schizophrenia is then presented, followed by a discussion of GABAergic compounds used in monotherapy or adjunctively in clinical schizophrenia studies.

Results: In basic studies, reductions in GABAergic neuronal density and abnormalities in receptors and reuptake sites have been identified in several cortical and subcortical GABA systems. A model has been developed suggesting GABA's role (including GABA-dopamine interactions) in schizophrenia. In several clinical studies, the use of adjunctive GABA agonists was associated with greater improvement in core schizophrenia symptoms.

Conclusions: Alterations in the GABA neurotransmitter system are found in clinical and basic neuroscience schizophrenia studies as well as animal models and may be involved in the pathophysiology of schizophrenia. The interaction of GABA with other well-characterized neurotransmitter abnormalities remains to be understood. Future studies should elucidate the potential therapeutic role for GABA ligands in schizophrenia treatment.

PubMed Disclaimer

Cited by

Genetic variation in GAD1 is associated with cortical thickness in the parahippocampal gyrus.
Brauns S, Gollub RL, Walton E, Hass J, Smolka MN, White T, Wassink TH, Calhoun VD, Ehrlich S. Brauns S, et al. J Psychiatr Res. 2013 Jul;47(7):872-9. doi: 10.1016/j.jpsychires.2013.03.010. Epub 2013 Apr 6. J Psychiatr Res. 2013. PMID: 23566421 Free PMC article.
Genome-wide gene pathway analysis of psychotic illness symptom dimensions based on a new schizophrenia-specific model of the OPCRIT.
Docherty AR, Bigdeli TB, Edwards AC, Bacanu S, Lee D, Neale MC, Wormley BK, Walsh D, O'Neill FA, Riley BP, Kendler KS, Fanous AH. Docherty AR, et al. Schizophr Res. 2015 May;164(1-3):181-6. doi: 10.1016/j.schres.2015.02.013. Epub 2015 Mar 13. Schizophr Res. 2015. PMID: 25778617 Free PMC article.
Reduced crowding and poor contour detection in schizophrenia are consistent with weak surround inhibition.
Robol V, Tibber MS, Anderson EJ, Bobin T, Carlin P, Shergill SS, Dakin SC. Robol V, et al. PLoS One. 2013 Apr 9;8(4):e60951. doi: 10.1371/journal.pone.0060951. Print 2013. PLoS One. 2013. PMID: 23585865 Free PMC article.
The SFT2D2 gene is associated with the autoimmune pathology of schizophrenia in a Chinese population.
Liu D, Wu L, Wei H, Zhu C, Tian R, Zhu W, Xu Q. Liu D, et al. Front Neurol. 2022 Dec 21;13:1037777. doi: 10.3389/fneur.2022.1037777. eCollection 2022. Front Neurol. 2022. PMID: 36619926 Free PMC article.
A systematic review of the role of the nociceptin receptor system in stress, cognition, and reward: relevance to schizophrenia.
Khan MS, Boileau I, Kolla N, Mizrahi R. Khan MS, et al. Transl Psychiatry. 2018 Feb 2;8(1):38. doi: 10.1038/s41398-017-0080-8. Transl Psychiatry. 2018. PMID: 29391391 Free PMC article. Review.

GABA and schizophrenia: a review of basic science and clinical studies - PubMed (original) (raw)